dihydroergotamine has been researched along with Cirrhosis in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Cheng, ZY; Dong, M; Jiang, R; Jiang, XX; Jin, WZ; Wang, Q; Xie, W; Yan, CL; Ye, RC; Yuan, SL; Zhang, HL; Zhang, Z; Zheng, KX; Zhou, HQ | 1 |
| Creutzig, A | 1 |
| Ghedira, H; Lacronique, J; Malaquin, F; Ostinelli, J; Urban, T | 1 |
4 other study(ies) available for dihydroergotamine and Cirrhosis
| Article | Year |
|---|---|
Dihydroergotamine ameliorates liver fibrosis by targeting transforming growth factor β type II receptor.
Topics: Animals; Dihydroergotamine; Fibrosis; Liver Cirrhosis; Mice; Molecular Docking Simulation; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2023 |
Fibrosis due to ergot derivatives: exposure to risk should be weighed up.
Topics: Dihydroergotamine; Ergotamine; Fibrosis; France; Humans; Methysergide; Risk Assessment; Risk Factors | 2002 |
[Ergotamine-induced heart valve fibrosis and coronary microangiopathy?].
Topics: Coronary Disease; Dihydroergotamine; Ergotamine; Fibrosis; Heart Valve Diseases; Heart Valves; Humans; Male; Middle Aged; Mitral Valve Insufficiency | 1992 |
Pleural and retroperitoneal fibrosis from dihydroergotamine.
Topics: Dihydroergotamine; Female; Fibrosis; Humans; Middle Aged; Pleural Diseases; Retroperitoneal Fibrosis | 1989 |